📰 Ophthalmic Solution News
Page 2 - Ophthalmic Solution News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ophthalmic Solution. Real-time updates on events, politics, business and more.
January 10, 2024
The share touched a 52-week high of Rs 1,429.95 and a 52-week low of Rs 628.10 on January 5, 2024 and March 31, 2023, respectively.
December 1, 2023
Generic Bromfenac Ophthalmic Solution is indicated for the treatment of post operative inflammation and reduction of ocular pain in patients who have under gone cataract surgery.
October 19, 2023
/PRNewswire/ -- DelveInsights Myopia Market Insights report includes a comprehensive understanding of current treatment practices, myopia emerging drugs,...
August 21, 2023
Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to...
August 16, 2023
Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its... -Today at 05:33 am- MarketScreener
August 16, 2023
Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bromfenac Ophthalmic Solution 0.09 per cent, Lupin said in a regulatory filing.
June 15, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica
May 16, 2023
Akorn has initiated a voluntary recall of various within-expiry drug products as the company has shut down operations.
April 28, 2023
Akorn has initiated a voluntary recall of various within-expiry drug products due to a company shutdown.